Vaxcyte, Inc. PCVX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$946.53M-23.5% | -$766.63M-16.7% | -$657.2M-20.0% | -$547.5M-7.4% | -$509.63M-9.9% | ||
| $16.39M-0.1% | $16.4M+39.4% | $11.76M+12.2% | $10.49M+17.0% | $8.96M+27.9% | ||
| $146.19M+5.3% | $138.85M+9.1% | $127.22M+12.4% | $113.18M+15.7% | $97.81M+15.3% | ||
| —— | —— | —— | —— | -$251K-101% | ||
| —— | —— | —— | —— | —— | ||
| $24.96M+40.9% | $17.72M+54.5% | $11.46M-4.7% | $12.03M— | —— | ||
| $9.45M+11.7% | $8.46M+4.7% | $8.08M-6.6% | $8.65M-0.2% | $8.67M-2.0% | ||
| —— | —— | —— | —— | $59.69M+42.5% | ||
| -$769.93M-17.4% | -$655.58M-20.9% | -$542.15M-18.0% | -$459.55M0.0% | -$459.78M-1.6% | ||
| $10.4M-24.2% | $13.71M-9.1% | $15.08M-6.9% | $16.2M-26.9% | $22.17M-1.1% | ||
| $1.48B+22.3% | $1.21B-30.1% | $1.73B-36.1% | $2.71B-0.1% | $2.71B-12.1% | ||
| $173.51M-0.7% | $174.69M+33.4% | $130.99M+9.9% | $119.16M+37.5% | $86.65M+29.4% | ||
| $80.63M-81.6% | $437.35M+286% | -$234.94M+81.5% | -$1.27B+11.0% | -$1.43B+28.6% | ||
| $15.99M+22.9% | $13.01M+35.6% | $9.59M-90.3% | $98.74M-51.1% | $202.02M+3.1% | ||
| $15M+36.4% | $10.99M-0.7% | $11.07M-32.6% | $16.43M+0.9% | $16.28M+13.9% | ||
| $602.84M+29,832% | $2.01M-55.4% | $4.51M-99.7% | $1.52B-6.6% | $1.63B-33.4% | ||
| $603K-75.3% | $2.44M-32.5% | $3.61M+260% | -$2.25M— | —— | ||
| -$85.86M+59.8% | -$213.77M+72.2% | -$768.96M-263% | -$211.71M+19.9% | -$264.45M-2,726% | ||
| $12.63M-12.5% | $14.43M-38.2% | $23.35M-14.1% | $27.19M-16.7% | $32.63M-15.7% | ||
| $25.95M-25.4% | $34.77M+55.0% | $22.43M-20.2% | $28.09M+1,078% | $2.39M+156% | ||
| —— | —— | —— | —— | $3.07M-67.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $59.69M+42.5% | ||
| —— | —— | —— | —— | $67.52M+35.2% | ||
| $50.21M+25.9% | $39.89M+21.6% | $32.81M+15.5% | $28.42M+16.1% | $24.48M-7.6% | ||
| $24.96M+40.9% | $17.72M+54.5% | $11.46M-4.7% | $12.03M— | —— | ||
| $9.45M+11.7% | $8.46M+4.7% | $8.08M-6.6% | $8.65M-0.2% | $8.67M-2.0% | ||
| $34.62M-20.0% | $43.26M-31.9% | $63.5M-28.2% | $88.41M-20.8% | $111.67M+15.4% | ||
| $1.43B-6.4% | $1.53B+5.8% | $1.45B+1.6% | $1.42B+7.1% | $1.33B+17.3% | ||
| $173.51M-0.7% | $174.69M+33.4% | $130.99M+9.9% | $119.16M+37.5% | $86.65M+29.4% | ||
| —— | $0-100% | $559.93M-50.0% | $1.12B-33.3% | $1.68B-25.0% | ||
| —— | —— | —— | —— | —— | ||
| $15.99M+22.9% | $13.01M-16.5% | $15.57M-42.3% | $27.01M— | —— | ||
| $10.41M+30.8% | $7.96M-41.7% | $13.64M+15.7% | $11.79M— | —— | ||
| —— | —— | —— | —— | $59.69M+42.5% | ||
| -$780.32M-16.6% | -$669.29M-20.1% | -$557.23M-17.1% | -$475.75M+1.3% | -$481.95M-1.5% | ||
| -$780.32M-16.6% | -$669.29M-20.1% | -$557.23M-17.1% | -$475.75M+1.3% | -$481.95M-1.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Vaxcyte, Inc. generate?
- Vaxcyte, Inc. (PCVX) generated -$769.9M in operating cash flow over the trailing twelve months.
- What is Vaxcyte, Inc.'s free cash flow?
- After $10.4M of capital expenditures, Vaxcyte, Inc.'s free cash flow was -$780.3M over the trailing twelve months, down 61.9% year over year.
- Where does Vaxcyte, Inc.'s cash flow data come from?
- Every line is extracted from Vaxcyte, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.